BioMarin Pharmaceutical
Develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions.
Launch date
Employees
Market cap
AUD24.8b
Enterprise valuation
AUD24.6b (Public information from Sep 2024)
Share price
$71.41 BMRN
San Rafael California (HQ)
Financials
Estimates*
USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Revenues | 1.9b | 1.8b | 2.1b | 2.4b | 2.8b | 3.1b | 3.4b |
% growth | 9 % | (1 %) | 14 % | 15 % | 16 % | 11 % | 10 % |
EBITDA | (5.8m) | 48.0m | 160m | 310m | 555m | 820m | 1.1b |
% EBITDA margin | - | 3 % | 8 % | 13 % | 20 % | 26 % | 31 % |
Profit | 859m | (64.1m) | 142m | 168m | 402m | 570m | 749m |
% profit margin | 46 % | (3 %) | 7 % | 7 % | 14 % | 18 % | 22 % |
EV / revenue | 8.4x | 8.6x | 9.3x | 7.5x | 5.9x | 5.1x | 4.4x |
EV / EBITDA | -2674.0x | 328.5x | 122.8x | 58.7x | 29.8x | 19.4x | 14.4x |
R&D budget | 628m | 629m | 650m | 747m | - | - | - |
R&D % of revenue | 34 % | 34 % | 31 % | 31 % | - | - | - |
Source: Dealroom estimates
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | N/A | IPO | |
Total Funding | - |
Related Content
Recent News about BioMarin Pharmaceutical
EditInvestments by BioMarin Pharmaceutical
EditACQUISITION by BioMarin Pharmaceutical Jan 2013
ACQUISITION by BioMarin Pharmaceutical Feb 2010
ACQUISITION by BioMarin Pharmaceutical Nov 2014
ACQUISITION by BioMarin Pharmaceutical Aug 2010